Business
Medicenna To Present Preliminary Top-Line Results on MDNA55 at the Immuno-Oncology Pharma Congress
Medicenna To Present Preliminary Top-Line Results on MDNA55 at the Immuno-Oncology Pharma ...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna To Present Preliminary Top-Line Results on MDNA55 at the Immuno-Oncology Pharma Congress\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen3{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:black 0pt; TEXT-ALIGN: LEFT; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prngen2{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: TOP; BORDER-BOTTOM:black 0pt; TEXT-ALIGN: LEFT; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prnsbt0{\nBORDER-TOP:0pt\n}\n.prnsbr0{\nBORDER-RIGHT:0pt\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n.prnsbl0{\nBORDER-LEFT:0pt\n}\n.prnsbb0{\nBORDER-BOTTOM:0pt\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, June 5, 2019\n\n\n\nTORONTO and HOUSTON, June 5, 2019 /CNW/ - Medicenna Therapeutics Corp.  (\"Medicenna\" or \"the Company\") (TSX: MDNA, OTCQB: MDNAF), a clinical stage Immuno-Oncology company, today announced that it will present preliminary top-line results from the recently completed Phase 2b clinical trial of MDNA55 for the treatment of recurrent glioblastoma at the Inaugural Immuno-Oncology Pharma Congress to be held from June 18-20, 2019 during World Pharma Week in Boston, MA.\nThe details of the oral presentation are as follows:\nPresenter:  \nDr. Fahar Merchant\nTitle: \nThe Art of War: Combating Recurrent Glioblastoma with MDNA55, an IL4 Guided Toxin - Interim Top-Line Phase 2b Results    \nDate/Time:\nTuesday, June 18, 2019 at 11:45am\nLocation: \nSeaport World Trade Center, 200 Seaport Boulevard, Boston, MA 02210\n \nIn addition, Medicenna will be presenting new preclinical data on its pipeline compound MDNA109, an IL2 Superkine, in a poster entitled: \"Engineering a long-acting CD122 biased IL-2 superkine displaying potent anti-tumoral response.\" The poster will be presented by Dr. Moutih Rafei, Head of Discovery at Medicenna Therapeutics.\nAbout Medicenna Medicenna is a clinical stage immunotherapy company focused on oncology and the development and commercialization of novel, high...